m Applications in Oncology
sample after therapy is necessary to detect molecular relapse before cytogenetic
or hematologic relapse. This is especially important in relapsed AML because survival rates are less than 20% [2]. Further studies on MRD are needed in order to
establish a biological basis on which clinical decisions are made and finally, most
importantly, to improve overall survival.
References
1. Munker R, Hiller E, Paquette R (2000) Modern Hematology. Humana Press, Totowa, New
Jersey
2. Loewenberg B, Downing JR, Burnett A (1999) Acute myeloid Leukemia. N Engl J Med
341:1051-1063
3. Bitter MA, Le Beau MM, Rowley JD, Larson RA, Golomb HM, Vardiman JW (1987) Associations between morphology, karyotype, and clinical features in myeloid leukemias. Hum
PathoI18(3):211-25
4. Liu Yin J A, Tobal K (1999) Detection of Minimal Residual Disease in Acute Myeloid
Leukemia: Methodologies, Clonical and Biological Significance. Br J Haematol 106:578-590
5. Rowley JD (1998) The critical role of chromosome translocations in human leukemias. Annu
Rev Genet. 32:495-519. Review
6. Downing JR, Head DR, Curcio-Brint AM, Hulshof MG, Motroni TA, Raimondi SC, Carroll AJ,
Drabkin HA, Willman C, Theil KS, et al (1993) An AMLlIETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia
containing the (8;21)(q22;q22) translocation. Blood 1;81(11):2860-5
7. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens
R, Burnett A, Goldstone A. (1998) The importance of diagnostic cytogenetics on outcome in
AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research
Council Adult and Children's Leukaemia Working Parties. Blood 1;92(7):2322-33
8. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N (1991) Establishment of a
human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation.
Blood 77(9):2031-6
9. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP (1997) Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 22(1):130-1, 134-138
10. Wittwer CT, Ririe KM, Andrew RV, David DA Gundry RA Balis UJ The LightCycler: Amicrovolume multisample fluorimeter with rapid temperature control. Biotechniques 1997;22: 176
11. Lion T (1996) Appropriate controls for RT-PCR. Leukemia 10(11):1843. Review
12. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross
NCP, Hochhaus A (1999) Accurate and Rapid Analysis of Residual Disease in Patients with
CML Using Specific Fluorescent Hybridization Probes for Real Time Quantitative RT-PCR.
Leukemia 13:1825-1832
13. Pui CH, Campana D (2000) New Definition of Remission in Childhood Acute Lymphoblastic Leukemia. Leukemia 14:783-785
sample after therapy is necessary to detect molecular relapse before cytogenetic
or hematologic relapse. This is especially important in relapsed AML because survival rates are less than 20% [2]. Further studies on MRD are needed in order to
establish a biological basis on which clinical decisions are made and finally, most
importantly, to improve overall survival.
References
1. Munker R, Hiller E, Paquette R (2000) Modern Hematology. Humana Press, Totowa, New
Jersey
2. Loewenberg B, Downing JR, Burnett A (1999) Acute myeloid Leukemia. N Engl J Med
341:1051-1063
3. Bitter MA, Le Beau MM, Rowley JD, Larson RA, Golomb HM, Vardiman JW (1987) Associations between morphology, karyotype, and clinical features in myeloid leukemias. Hum
PathoI18(3):211-25
4. Liu Yin J A, Tobal K (1999) Detection of Minimal Residual Disease in Acute Myeloid
Leukemia: Methodologies, Clonical and Biological Significance. Br J Haematol 106:578-590
5. Rowley JD (1998) The critical role of chromosome translocations in human leukemias. Annu
Rev Genet. 32:495-519. Review
6. Downing JR, Head DR, Curcio-Brint AM, Hulshof MG, Motroni TA, Raimondi SC, Carroll AJ,
Drabkin HA, Willman C, Theil KS, et al (1993) An AMLlIETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia
containing the (8;21)(q22;q22) translocation. Blood 1;81(11):2860-5
7. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens
R, Burnett A, Goldstone A. (1998) The importance of diagnostic cytogenetics on outcome in
AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research
Council Adult and Children's Leukaemia Working Parties. Blood 1;92(7):2322-33
8. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N (1991) Establishment of a
human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation.
Blood 77(9):2031-6
9. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP (1997) Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 22(1):130-1, 134-138
10. Wittwer CT, Ririe KM, Andrew RV, David DA Gundry RA Balis UJ The LightCycler: Amicrovolume multisample fluorimeter with rapid temperature control. Biotechniques 1997;22: 176
11. Lion T (1996) Appropriate controls for RT-PCR. Leukemia 10(11):1843. Review
12. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross
NCP, Hochhaus A (1999) Accurate and Rapid Analysis of Residual Disease in Patients with
CML Using Specific Fluorescent Hybridization Probes for Real Time Quantitative RT-PCR.
Leukemia 13:1825-1832
13. Pui CH, Campana D (2000) New Definition of Remission in Childhood Acute Lymphoblastic Leukemia. Leukemia 14:783-785